Sanofi’s latest fair value estimate has been nudged down from €106.26 to €105.20 as analysts factor in slightly softer revenue growth assumptions, even as the company’s overall risk profile remains ...
With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...
The Punch on MSN
Kano signs partnership to address rising diabetes cases
Kano State partners with Sanofi to combat rising diabetes cases, improving access to insulin, training healthcare workers, ...
Dupixent For Moderate-To-Severe Asthma Treatment Market Expected To Reach ~$8.1 Billion By 2032. December 13, 2025 7:27 am - The Dupixent market for moderate-to-severe asthma is valued at $3.25 ...
Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...
Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...
The US Food and Drug Administration (FDA) on Friday announced it has approved two new oral medicines to treat a common ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended five novel medicines for approval at its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback